Santoni, M., Myint, Z., Büttner, T., Takeshita, H., Okada, Y., Lam, E. T., . . . Porta, C. (2023). Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: The ARON-2 study.
Citace podle Chicago (17th ed.)Santoni, Matteo, et al. Real-world Effectiveness of Pembrolizumab as First-line Therapy for Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma: The ARON-2 Study. 2023.
Citace podle MLA (9th ed.)Santoni, Matteo, et al. Real-world Effectiveness of Pembrolizumab as First-line Therapy for Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma: The ARON-2 Study. 2023.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..